Maven Clinic vs Labcorp
Side-by-side comparison of AI visibility scores, market position, and capabilities
Maven Clinic is the largest virtual clinic for women and families, providing care across fertility, maternity, menopause, and pediatrics through employer and health plan benefits.
About
Maven Clinic is a digital health company founded in 2014 by Kate Ryder that has grown into the largest virtual care platform dedicated to women and family health, raising over $300M at a $1.35B valuation. The company provides a comprehensive virtual clinic covering fertility, maternity, menopause, family planning, pediatric care, and general women's health through a network of OB-GYNs, midwives, reproductive endocrinologists, nutritionists, mental health specialists, and other providers. Maven distributes primarily through employer health benefits programs and health plan partnerships, serving over 30 million covered lives through partnerships with large employers and insurers. The platform has demonstrated significant return on investment for employers through reduced NICU costs, lower preterm birth rates, and improved fertility treatment outcomes. Maven has expanded internationally to serve global employers managing diverse populations across multiple countries. The company competes with Progyny in fertility benefits and with Hims & Hers and other women's health platforms in the direct-to-consumer market while maintaining the broadest clinical scope of any women's and family health platform.
Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.
About
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.